Streetbeat News

Products Services

AZN

AstraZeneca's FARXIGA (Dapagliflozin) has received FDA approval to improve glycemic control in pediatric patients with Type-2 Diabetes aged 10 years and older. This approval is based on positive results from the pediatric T2NOW Phase III trial.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 9:38 pm

MAPS

Weedmaps (NASDAQ:MAPS) has released data on New York's cannabis market for Q1 2024, revealing consumer preferences and spending habits. Cannabis flower is the most popular product, with edibles also seeing high demand. The average order value in New York is significantly higher than the national average. Weedmaps is actively involved in community initiatives and supporting the legal market transition. New York has also approved home cannabis cultivation rules and issued 105 new adult-use licenses.

Portfolio Pulse from Patricio Liddle

June 12, 2024 | 9:26 pm

FLOKIUSD

GME

SHIBUSD

Keith Gill, known for his role in the GameStop stock surge, has returned to social media, causing a significant increase in the value of the meme coin GME on Solana. This has led to GME on Sol being listed on multiple exchanges and achieving high trading volumes. The coin's community and new initiatives are driving its growth.

Portfolio Pulse from Justin Roberti

June 12, 2024 | 9:23 pm

RTX

NASA has awarded Raytheon a contract worth $506.7 million to provide three instruments and related services for the Landsat Next mission. The contract includes a cost-plus-award-fee base period and a cost-plus-fixed-fee option period. The work will be primarily conducted at Raytheon's facilities in El Segundo, California.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:52 pm

AVGO

Broadcom Inc (NASDAQ:AVGO) reported strong Q2 earnings, beating revenue and EPS estimates driven by AI demand. The company announced a 10-for-1 stock split and raised its fiscal-year 2024 revenue guidance. Shares rose 10.53% in after-hours trading.

Portfolio Pulse from Adam Eckert

June 12, 2024 | 8:44 pm

CLLS

Cellectis has published a scientific article in Nature Communications, revealing a non-viral gene therapy approach for treating Sickle Cell Disease.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:38 pm

GVA

Granite has executed a long-term lease with the Port of Woodland for a new construction materials facility on a 25-acre site next to the Columbia River. This move reinforces Granite's commitment to the Southwest Washington area home market.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:36 pm

AEE

Ameren's subsidiary has received approval from the Missouri Public Service Commission to purchase a 150-MW solar facility currently under construction in Cass County, Illinois.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:35 pm

PFE

Pfizer announced that key secondary endpoints in a Phase 3 study of its investigational gene therapy, Fordadistrogene Movaparvovec, did not show a significant difference between participants treated with the therapy and those given a placebo.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:33 pm

PFE

Pfizer announced that its Phase 3 CIFFREO study evaluating the investigational mini-dystrophin gene therapy, Fordadistrogene Movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy did not meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 8:31 pm